MedTrace Logo

Use of a Subcutaneous Catheter for Controlled Ovarian Stimulation

NCT05505474 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-11-18

No results posted yet for this study

Summary

Subcutaneous medications are an integral part of controlled ovarian stimulation protocols for in-vitro fertilization (IVF), but daily or twice daily injections are both physically and emotionally burdensome for patients and their partners. This is a feasibility study to evaluate the use of the Neria Guard™ (Unomedical, Convatec) subcutaneous catheter for ovarian stimulation in IVF.

Conditions

  • Infertility, Female

Interventions

DEVICE

IVF with the Neria™ Guard Subcutaneous Catheter

Use of the Neria™ Guard subcutaneous catheter for administration of subcutaneous medication in an IVF cycle.

Sponsors & Collaborators

  • ConvaTec Inc.

    collaborator INDUSTRY

  • University of Southern California

    lead OTHER

Principal Investigators

  • Richard J Paulson, MD · University of Southern California

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-02
Primary Completion
2024-12-31
Completion
2024-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05505474 on ClinicalTrials.gov